MHRA: Tibolone (Livial) increases risk of breast cancer recurrence

The Medicines and Healthcare products Regulatory Agency (UK) warned in the February 2009 Drug Safety Advice about the increased breast cancer recurrence in patients treated with tibolone (Livial): Treatment for breast cancer (e.g., tamoxifen) can commonly exacerbate menopausal symptoms. Although tibolone is contraindicated in women with known or suspected breast cancer, and in those with […]

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos